ガニレリクス酢酸塩
ガニレリクス酢酸塩 物理性質(zhì)
- 貯蔵溫度 :
- -20°C
- 溶解性:
- DMF: 30 mg/ml; DMSO: 30 mg/ml; Ethanol: 0.25 mg/ml; PBS (pH 7.2): 10 mg/ml
- 酸解離定數(shù)(Pka):
- 4.2 (3-pyridinylalanine); 9.8 (tyrosine)
- 外見(jiàn) :
- 凍結(jié)乾燥粉末
- 色:
- 白い
- InChIKey:
- GJNXBNATEDXMAK-PFLSVRRQSA-N
ガニレリクス酢酸塩 価格
もっと(8)
| メーカー |
製品番號(hào) |
製品説明 |
CAS番號(hào) |
包裝 |
価格 |
更新時(shí)間 |
購(gòu)入 |
|
富士フイルム和光純薬株式會(huì)社(wako)
|
W01TRCG245000 |
Ganirelix TFA Salt (>90%)
Ganirelix Trifluoroacetic Acid Salt (>90%) |
129311-55-3 |
1mg |
￥52200 |
2024-03-01 |
購(gòu)入 |
|
富士フイルム和光純薬株式會(huì)社(wako)
|
W01TRCG245000 |
Ganirelix TFA Salt (>90%)
Ganirelix Trifluoroacetic Acid Salt (>90%) |
129311-55-3 |
5mg |
￥195300 |
2024-03-01 |
購(gòu)入 |
|
Sigma-Aldrich Japan
|
SML0241 |
≥95% (HPLC)
Ganirelix acetate salt ≥95% (HPLC) |
129311-55-3 |
1mg |
￥27600 |
2024-03-01 |
購(gòu)入 |
|
Sigma-Aldrich Japan
|
SML0241 |
≥95% (HPLC)
Ganirelix acetate salt ≥95% (HPLC) |
129311-55-3 |
5mg |
￥127000 |
2024-03-01 |
購(gòu)入 |
|
富士フイルム和光純薬株式會(huì)社(wako)
|
W01TRCG245000 |
Ganirelix TFA Salt (>90%)
Ganirelix Trifluoroacetic Acid Salt (>90%) |
129311-55-3 |
10mg |
￥312600 |
2024-03-01 |
購(gòu)入 |
ガニレリクス酢酸塩 化學(xué)特性,用途語(yǔ),生産方法
効能
性腺刺激ホルモン放出ホルモン受容體拮抗薬
商品名
ガニレスト (MSD)
説明
Ganirelix acetate was introduced in Germany as prefilled syringes for subcutaneous
injections that inhibit premature luteinizing hormone surges in women undergoing
controlled ovarian hyperstimulation. This decapeptide analog of luteinizing hormonereleasing
hormone (LH-RH) is the second third-generation LH-RH antagonist to be
launched after citrorelix (Asta Medica). This highly bioavailable compound immediately
blocks the endogenous release by the pituitary gland of luteinizing hormone (LH) and
follicle-stimulating hormone (FSH), the hormone that induces ovulation. After
discontinuation of the treatment, the pituitary-gonadal function is rapidly recovered due to
its short-half life. As a consequence, ganirelix at daily doses of 0.25 mg S.C. efficiently
prevented LH surges during clinical trials in infertile women under controlled ovarian
hyperstimulation with recombinant FSH before in vitro fertilization or similar reproductive
techniques. Unlike first and second-generation gonadotropin-releasing hormone
antagonists, ganirelix has minimal histamine-releasing effects thus avoiding the formation of edema of the face and extremities. Ganirelix is very resistant to hydrolysis and, in contrast to the already established cetrorelix, has good water solubility.
使用
Decapeptide LH-RH antagonist. Used in treatment of infertility.
ガニレリクス酢酸塩 上流と下流の製品情報(bào)
原材料
準(zhǔn)備製品
ガニレリクス酢酸塩 生産企業(yè)
Global( 78)Suppliers
129311-55-3(ガニレリクス酢酸塩)キーワード:
- 129311-55-3
- N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-[bis(ethylaMino)Methylene]-D-lysyl-L-leucyl-N6-[bis(ethylaMino)Methylene]-L-lysyl-L-prolyl-
- Ganirelix acetate salt
- N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-[bis(ethylamino)methylene]-D-lysyl-L-leucyl-N6-[bis(ethylamino)methylene]-L-lysyl-L-prolyl-D-alaninamide diacetate
- Ganirelix USP/EP/BP
- Ganirelix Diacetate salt
- GANIRELIX TFA SALT (>90%)
- ガニレリクス酢酸塩
- ガニレリクス酢酸塩 (JAN)